Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: The University of Texas Health Science Center, Houston
The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).
This description comes directly from the study's public registry record.
Putao Cen, MD · (832) 325-7705 · pancreasresearch@uth.tmc.edu
Ayodeji Adeniji · (713) 500-5377 · Ayodeji.Adeniji@uth.tmc.edu
Always discuss trial participation with your own doctor first.
| The University of Texas Health Science Center at Houston | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06831136